New York, July 19, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Infusion Pumps and Devices: Technologies and Global Markets" - https ...
Liquidia and Sandoz have also extended the term of their promotion agreement for Treprostinil Injection until 2032 MORRISVILLE, N.C., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: ...
An implantable infusion pump is a sophisticated medical device designed to deliver medications directly to patients through various routes, including intra-arterial, intravenous, subcutaneous, ...
An international, multisite phase 3 trial co-led by a University of Cincinnati researcher found Parkinson’s disease medication delivered through an infusion pump is safe and effective at reducing ...
A therapy for Parkinson’s disease that can be delivered by a 24-hour subcutaneous infusion pump has been recommended for use by the NHS and could be an option for hundreds of patients with the ...
An international, multisite phase 3 trial co-led by a University of Cincinnati researcher found Parkinson’s disease medication delivered through an infusion pump is safe and effective at reducing ...
The expanded approval was based on data from the phase 3 PRONTO-PUMP-2 trial which evaluated Lyumjev vs Humalog for use in insulin pump therapy in 432 adults with type 1 diabetes. The Food and Drug ...
Designed for advanced Parkinson’s with poorly controlled motor fluctuations, the infusion delivers steadier levodopa exposure than pills via continuous subcutaneous dosing.
The infusion pumps market is expected to grow significantly, with a projected valuation of US$ 641.7 million by 2023. The market exhibits a noteworthy pattern, with a compound annual growth rate (CAGR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results